Protagonist Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Protagonist Therapeutics

08/08/2022 13:02

* Protagonist Therapeutics Inc  PTGX.OQ  reported a
quarterly
adjusted loss of 84 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 93 cents per share.
    * Revenue fell 62.1% to $859.00 thousand from a year ago;
analysts
expected $383.33 thousand. 
    * Protagonist Therapeutics Inc's reported EPS for the
quarter was
a loss of 84 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Protagonist Therapeutics Inc shares had risen by 44.9%
this
quarter and lost 66.5% so far this year.
    * The company reported a quarterly loss of $41.04 million.
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $40.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 8
at 12:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.93          -0.84          Beat
 Mar. 31 2022      -0.63          -0.43          Beat
 Dec. 31 2021      -0.78          -0.77          Beat
 Sep. 30 2021      -0.67          -0.70          Missed